Evidence map›Paper›PMID 28299283›Full record

ArticleFrontiers in oncology2017

Lenvatinib for Anaplastic Thyroid Cancer.

Makoto Tahara, Naomi Kiyota, Tomoko Yamazaki, Naoko Chayahara, Kenji Nakano, Lina Inagaki, Kazuhisa Toda, Tomohiro Enokida, Hironobu Minami, Yoshinori Imamura and 5 more

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01728623 (A Phase 2 Study of E7080 in Subjects With Advanced Thyroid Cancer), which is not on this map. Cited by 96 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
96citing papers in PubMed, 4 pooled it
14.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01728623 phase2completednot on this map

A Phase 2 Study of E7080 in Subjects With Advanced Thyroid Cancer

TypeinterventionalSponsorEisai Co., Ltd.Ran2012 to 2015Enrolled51ConditionsThyroid CancerArmsE7080 capsule
3 · Its place in the literature

Who cites it

96 citing papers in PubMed, 4 syntheses or guidelines pooled it, 189 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Cabozantinib plus Atezolizumab in Advanced, Progressive Endocrine Malignancies: A Multicohort, Basket, Phase II Trial (CABATEN/GETNE-T1914).Clinical cancer research : an official journal of the American Association for Cancer Research · 2025
    Trial
  6. Trial
  7. Trial
  8. Open-Label, Single-Arm, Multicenter, Phase II Trial of Lenvatinib for the Treatment of Patients With Anaplastic Thyroid Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2021
    Trial
  9. Article
  10. Review
  11. Article
  12. Article
  13. Observational
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Article

36 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 2 countries.

Makoto TaharaDepartment of Head and Neck Medical Oncology, National Cancer Center Hospital East , Kashiwa , Japan.
Naomi KiyotaDepartment of Medical Oncology and Hematology, Kobe University Hospital , Kobe , Japan.
Tomoko YamazakiDepartment of Head and Neck Medical Oncology, National Cancer Center Hospital East , Kashiwa , Japan.
Naoko ChayaharaDepartment of Medical Oncology and Hematology, Kobe University Hospital , Kobe , Japan.
Kenji NakanoDepartment of Medical Oncology, Cancer Institute Hospital of the Japanese Foundation for Cancer Research , Tokyo , Japan.
Lina InagakiDepartment of Medical Oncology, Cancer Institute Hospital of the Japanese Foundation for Cancer Research , Tokyo , Japan.
Kazuhisa TodaDepartment of Head and Neck Surgery, Cancer Institute Hospital of the Japanese Foundation for Cancer Research , Tokyo , Japan.
Tomohiro EnokidaDepartment of Head and Neck Medical Oncology, National Cancer Center Hospital East , Kashiwa , Japan.
Hironobu MinamiDepartment of Medical Oncology and Hematology, Kobe University Hospital , Kobe , Japan.
Yoshinori ImamuraDepartment of Medical Oncology and Hematology, Kobe University Hospital , Kobe , Japan.
Tatsuya SasakiEisai Co. Ltd. , Tokyo , Japan.
Takuya SuzukiEisai Co. Ltd. , Tokyo , Japan.
Katsuki FujinoEisai Co. Ltd. , Tokyo , Japan.
Corina E DutcusEisai Inc. , Woodcliff Lake, NJ , USA.
Shunji TakahashiDepartment of Medical Oncology, Cancer Institute Hospital of the Japanese Foundation for Cancer Research , Tokyo , Japan.
Japanese Foundation For Cancer Research · JPKobe University Hospital · JPEisai (Japan) · JPNational Cancer Center Hospital East · JPEisai (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLenvatinib has been approved by regulatory agencies in Japan, the United States, and the European Union for treatment of radioiodine-refractory differentiated thyroid cancer (RR-DTC). Thyroid cancer, however, is a clinically diverse disease that includes anaplastic thyroid cancer (ATC), the subtype associated with the highest lethality. Effective therapy for ATC is an unmet need. PATIENTS AND

methodsThis phase 2, single-arm, open-label study in patients with thyroid cancer, including ATC, RR-DTC, and medullary thyroid cancer was conducted from 3 September 2012 to 9 July 2015. Patients received lenvatinib 24 mg daily until disease progression or development of unacceptable toxicity. The primary endpoint was safety, and the secondary endpoint was efficacy, as assessed by progression-free survival (PFS), overall survival (OS), and objective response rate.

resultsAt data cutoff, 17 patients with ATC were enrolled. All experienced ≥1 treatment-emergent adverse event (TEAE). The most frequent TEAEs were decreased appetite (82%), hypertension (82%), fatigue (59%), nausea (59%), and proteinuria (59%). Of note, only one patient required lenvatinib withdrawal because of a TEAE, and this TEAE was considered unrelated to lenvatinib. The median PFS was 7.4 months [95% confidence interval (CI): 1.7-12.9], the median OS was 10.6 months (95% CI: 3.8-19.8), and the objective response rate was 24%.

conclusionIn this study, lenvatinib demonstrated manageable toxicities with dose adjustments and clinical activity in patients with ATC. This clinical activity of lenvatinib warrants further investigation in ATC. CLINICALTRIALSGOV: NCT01728623.

Indexed as

anaplastic thyroid cancerclinical triallenvatinibphase 2tyrosine kinase inhibitor

Identifiers

PMID28299283
PMCPMC5331066
OpenAlexW2599999454

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.